::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A STUDY TO ASSESS THE IMPORTANCE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) AS AN ADJUVANT IN THE TREATMENT OF NEONATAL SEPSIS IN PRETERM BABIES

AUTHORS:

Dr Amina Mannan Malik, Dr Rida Maria, Dr Seemab Safdar

ABSTRACT:

Introduction: Newborn children conceived before 32 weeks of incubation are genuinely immune deficient with cord blood centralization of IgG being not as much as half contrasted with those found in infants conceived at full term. Furthermore, exceptionally preterm newborn children have lessened supplement components, polymorphonuclear chemotaxis and are obligated to debilitate their capacity pools. Goals and Goals: An attempt was made to conduct this planned study with accompanying goals to focus on administering IVIG in addition to antibiotics to improve the therapeutic consequences of sepsis in premature infants. Materials and Methods: Sixty preterm infants with sepsis were randomly assigned to study and control groups in the Neonatal Intensive Care Unit of Fauji Foundation Hospital, Rawalpindi for one-year duration from May 2019 to April 2020. The study group was given IVIG in addition to standard treatment. Results: A total of 60 patients were enrolled, 30 in the study and 30 in the control group. There were no differences between the sexes (male 50%, females 50%) of the included newborns, which is also visible in the study (men 47.7%, women 52.3%) and the control group (males 52.3%, females 47.7 %). Conclusion: The low level of immunity in premature babies causes increased morbidity and mortality in severe infections. Using IVIG along with antibiotics and other supportive therapies may improve outcome. Key words: IVIG, neonatal sepsis, premature babies.